PL425970A1 - Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu - Google Patents

Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu

Info

Publication number
PL425970A1
PL425970A1 PL425970A PL42597018A PL425970A1 PL 425970 A1 PL425970 A1 PL 425970A1 PL 425970 A PL425970 A PL 425970A PL 42597018 A PL42597018 A PL 42597018A PL 425970 A1 PL425970 A1 PL 425970A1
Authority
PL
Poland
Prior art keywords
triazol
phenyl
phenol
derivatives
amidosulfate
Prior art date
Application number
PL425970A
Other languages
English (en)
Other versions
PL239999B1 (pl
Inventor
Sebastian DEMKOWICZ
Mateusz Daśko
Janusz RACHOŃ
Original Assignee
Politechnika Gdańska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Gdańska filed Critical Politechnika Gdańska
Priority to PL425970A priority Critical patent/PL239999B1/pl
Priority to EP18786433.5A priority patent/EP3790868B1/en
Priority to CA3101768A priority patent/CA3101768C/en
Priority to US17/252,703 priority patent/US11939303B2/en
Priority to JP2020570953A priority patent/JP7160387B2/ja
Priority to PCT/PL2018/000080 priority patent/WO2019245393A1/en
Publication of PL425970A1 publication Critical patent/PL425970A1/pl
Publication of PL239999B1 publication Critical patent/PL239999B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Przedmiotem zgłoszenia są amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu oraz pochodne 4-(1-fenylo-1H-|1,2,3]triazol-4-ylo)-fenolu jako nowe związki. Przedmiotem zgłoszenia jest też pierwsze zastosowanie medyczne amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu oraz pierwsze zastosowanie medyczne pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu. Przedmiotem zgłoszenia jest również zastosowanie nowych związków jako środka o właściwościach inhibitora sulfatazy steroidowej i/lub modulatora receptora estrogenowego. Zgłoszenie obejmuje też zastosowanie nowych związków jako środka przeciwdrobnoustrojowego i/lub modulatora receptora estrogenowego. W szczególności amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu znajdują zastosowanie medyczne jako leki w terapii nowotworowej. Przedmiotem zgłoszenia jest ponadto sposób otrzymywania tych nowych związków, przy czym pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu stanowią produkt pośredni, z którego bezpośrednio otrzymuje się pochodne amidosiarczanowe.
PL425970A 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu PL239999B1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL425970A PL239999B1 (pl) 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu
EP18786433.5A EP3790868B1 (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
CA3101768A CA3101768C (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1- phenyl-1h-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
US17/252,703 US11939303B2 (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
JP2020570953A JP7160387B2 (ja) 2018-06-18 2018-08-20 ４－（１－フェニル－１ｈ－［１，２，３］トリアゾール－４－イル）－フェノールのスルファメート誘導体、４－（１－フェニル－１ｈ－［１，２，３］トリアゾール－４－イル）－フェノールの誘導体、それらの医療用途、および４－（１－フェニル－１ｈ－［１，２，３］トリアゾール－４－イル）－フェニルスルファメート誘導体を得る方法
PCT/PL2018/000080 WO2019245393A1 (en) 2018-06-18 2018-08-20 Sulfamate derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1h-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL425970A PL239999B1 (pl) 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu

Publications (2)

Publication Number Publication Date
PL425970A1 true PL425970A1 (pl) 2020-01-02
PL239999B1 PL239999B1 (pl) 2022-02-07

Family

ID=63858012

Family Applications (1)

Application Number Title Priority Date Filing Date
PL425970A PL239999B1 (pl) 2018-06-18 2018-06-18 A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu

Country Status (6)

Country Link
US (1) US11939303B2 (pl)
EP (1) EP3790868B1 (pl)
JP (1) JP7160387B2 (pl)
CA (1) CA3101768C (pl)
PL (1) PL239999B1 (pl)
WO (1) WO2019245393A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939303B2 (en) 2018-06-18 2024-03-26 Politechnika Gdanska Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4320089B2 (ja) * 1999-07-06 2009-08-26 あすか製薬株式会社 フェニルスルファメート誘導体
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound
US9045442B2 (en) * 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
US20110201656A1 (en) * 2008-08-08 2011-08-18 Neurosearch A/S Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0914767D0 (en) * 2009-08-24 2009-09-30 Sterix Ltd Compound
BR112016015578A2 (pt) 2014-01-03 2017-08-08 Elexopharm Gmbh Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
PL239999B1 (pl) 2018-06-18 2022-02-07 Politechnika Gdanska A midosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol- -4-ylo)-fenolu, ich zastosowanie medyczne i diagnostyczne, oraz sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo- 1H-[1,2,3]triazol-4-ylo)-fenolu

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11939303B2 (en) 2018-06-18 2024-03-26 Politechnika Gdanska Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives

Also Published As

Publication number Publication date
EP3790868A1 (en) 2021-03-17
CA3101768C (en) 2023-12-05
US20210188785A1 (en) 2021-06-24
EP3790868B1 (en) 2023-01-11
CA3101768A1 (en) 2019-12-26
WO2019245393A1 (en) 2019-12-26
US11939303B2 (en) 2024-03-26
PL239999B1 (pl) 2022-02-07
JP7160387B2 (ja) 2022-10-25
JP2022501310A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
SG11201907038WA (en) Quinazoline compound
BR112017021688A2 (pt) composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
MA40240B1 (fr) Composés hétéroaryle d'inhibition de la kinase
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112022012110A2 (pt) Compostos e métodos para a degradação direcionada de receptor androgênico
PH12020552060A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
EP4410291A3 (en) Erbb receptor inhibitors
ECSP20063690A (es) Anticuerpos
BR112019023846A2 (pt) composição farmacêutica de anticorpo de pd-l1 e uso da mesma
BR112021020681A2 (pt) Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PL425970A1 (pl) Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu
Smith Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy
MX2021015486A (es) Derivado de indazol, metodo de preparacion y aplicacion farmaceutica del mismo.
EP3852760A4 (en) MATTER ON THE COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF THE ANALOGUES DERIVED FROM FL118 PLATFORM POSITIONS 7 AND 9 FOR THE TREATMENT OF HUMAN DISEASES
BR112016014601A2 (pt) Composição dermatológica, dispositivo aplicador e método para preparar uma composição dermatológica
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
BR112019000706A8 (pt) Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo